Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: Final induction results of cancer and leukemia group B study 9621

Journal of Clinical Oncology

Volumn 22, Issue 21, 2004, Pages 4290-4301

  Kolitz, Jonathan E ^a   George, Stephen L ^a   Dodge, Richard K ^a   Hurd, David D ^a   Powell, Bayard L ^a   Allen, Steven L ^a   Velez Gardcia, Enrique ^a   Moore, Joseph O ^a   Shea, Thomas C ^a   Hoke, Eva ^a   Caligiuri, Michael A ^a   Vardiman, James W ^a   Bloomfield, Clara D ^a   Larson, Richard A ^a  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; VALSPODAR; ANTINEOPLASTIC AGENT; CYCLOSPORIN DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TOXICITY; ACUTE DISEASE; CLINICAL TRIAL; DRUG RESISTANCE; MIDDLE AGED; MYELOID LEUKEMIA; STATISTICAL MODEL; SURVIVAL; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOSPORINS; CYTARABINE; DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; HUMANS; LEUKEMIA, MYELOID; LOGISTIC MODELS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 16544385074     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.11.106     Document Type: Article

References (47)

1. Leith CP, Kopecky KJ, Chen IM, et al: Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group Study. Blood 94:1086-1099, 1999
2. Leith CP, Kopecky KJ, Godwin J, et al: Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy-A Southwest Oncology Group study. Blood 89:3323-3329, 1997
3. te Boekhorst PA, de Leeuw K, Schoester M, et al: Predominance of functional multidrug resistance (MDR-D phenotype in CD34+ acute myeloid leukemia cells. Blood 82:3157-3162, 1993
4. van den Heuvel-Eibrink MM, van der Holt B, te Boekhorst PA, et al: MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia. Br J Haematol 99:76-83, 1997
5. Samdani A, Vijapurkar U, Grimm MA, et al: Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML). Leuk Res 20: 175-180, 1996
6. Wuchter C, Leonid K, Ruppert V, et al: Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 85:711-721, 2000
7. te Boekhorst PA, Lowenberg B, van Kapel J, et al: Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. Leukemia 9:1025-1031, 1995
8. Coley HM, Twentyman PR, Workman P: Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A. Biochem Pharmacol 38:4467-4475, 1989
9. Fukushima T, Yamashita T, Yoshio N, et al: Effect of PSC 833 on the cytotoxicity of idarubicin and idarubicinol in multidrug-resistant K562 cells. Leuk Res 23:37-42, 1999
10. Jiang XR, Kelsey SM, Wu YL, et al: Circumvention of P-glycoprotein- mediated drug resistance in human leukaemic cells by nonimmunosuppressive cyclosporin D analogue, SDZ PSC 833. Br J Haematol 90:375-383, 1995
11. Ross DD, Wooten PJ, Sridhara R, et al: Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood 82:1288-1299, 1993
12. Pourtier-Manzanedo A, Didier AD, Muller CD, et al: SDZ PSC 833 and SDZ 280-446 are the most active of various resistance-modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells. Anticancer Drugs 3:419-425, 1992
13. Merlin JL, Guerci AP, Marchal S, et al: Influence of SDZ-PSC833 on daunorubicin intracellular accumulation in bone marrow specimens from patients with acute myeloid leukaemia. Br J Haematol 103:480-487, 1998
14. Duraj J, Takacsova X, Sedlak J, et al: PSC 833 induces apoptosis in drug-sensitive human leukemia cell line and modulates resistance to paclitaxel in its multidrug-resistant variant. Anticancer Res 20:4627-4632, 2000
15. Sikic BI, Fisher GA, Lum BL, et al: Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 40:S13-S19, 1997
16. Goulding CW, Giuliano AE, Cabot MC: SDZ PSC 833 the drug resistance modulator activates cellular ceramide formation by a pathway independent of P-glycoprotein. Cancer Lett 149:143-151, 2000
17. List AF, Kopecky KJ, Willman CL, et al: Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group study. Blood 98:3212-3220, 2001
18. Visani G, Milligan D, Leoni F, et al: Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia. Leukemia 15:764-771, 2001
19. Kornblau SM, Estey E, Madden T, et al: Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 15:1796-1802, 1997
20. Advani R, Saba HI, Tallman MS, et al: Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 93:787-795, 1999
21. Lee EJ, George SL, Caligiuri M, et al: Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: Results of cancer and leukemia group B study 9420. J Clin Oncol 17:2831-2839, 1999
22. Chauncey TR, Rankin C, Anderson JE, et al: A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: A Southwest Oncology Group study 9617. Leuk Res 24:567-574, 2000
23. Sonneveld P, Burnett A, Vossebeld P, et al: Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia. Hematol J 1:411-421, 2000
24. Baer MR, George SL, Dodge RK, et al: Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100:1224-1232, 2002
25. Greenberg PL, Lee SJ, Advani R, et al: Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelody splastic syndrome: A phase III trial (E2995). J Clin Oncol 22:1078-1086, 2004
26. Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemotherapy in adults with acute myeloid leukemia: Cancer and Leukemia Group B. N Engl J Med 331:895-903, 1994
27. Bloomfield CD, Lawrence D, Byrd JC, et al: Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173-4179, 1998
28. Byrd JC, Dodge RK, Carroll A, et al: Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 17:3767-3775, 1999
29. Moore JO, Powell B, Velez-Garcia E, et al: A comparison of sequential non-cross-resistant therapy or Ara-C consolidation following complete remission in adult patients < 60 years with acute myeloid leukemia: CALGB 9222. Proc Am Soc Clin Oncol 16:48, 1997 (abstr 50)
30. Kolitz JE, George SL, Dodge RK, et al: Consolidation therapy by cytogenetic risk in adults with acute myeloid leukemia < 60 years in first complete remission: Results of CALGB 9621. Blood 98:688a, 2001 (abstr 2879)
31. Kolitz JE, George SL, Barrier R, et al: Treatment of core binding factor (CBF) acute myeloid leukemia (AML) with post-remission high-dose cytarabine (HiDAC): Results from CALGB 9621. Blood 102:176a, 2003 (abstr 612)
32. Kolitz JE, George SL, Barrier R, et al: A novel post-remission consolidation regimen for patients with acute myeloid leukemia (AML) < 60 years old with normal or unfavorable cytogenetics: Results from CALGB 9621. Blood 102: 175a, 2003 (abstr 609)
33. Weiss RB, Vogelzang NJ, Peterson BA, et al: A successful system of scientific data audits for clinical trials: A report from the Cancer and Leukemia Group B. JAMA 270:459-464, 1993
34. Cheson BD, Cassileth PA, Head DR, et al: Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813-819, 1990
35. Hosmer DW, Lemeshow S: Applied Logistic Regression. New York, John Wiley & Sons, 1989
36. Kaplan EL, Meier P: Nonparametric estimation for incomplete observations. J Am Stat Assoc 53:457-481, 1958
37. Altman DG: Practical Statistics for Medical Research. London, Chapman & Hall, 1991
38. Byrd JC, Mrozek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325-4336, 2002
39. Advani R, Fisher GA, Lum BL, et al: A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. Clin Cancer Res 7:1221-1229, 2001
40. Filipits M, Suchomel RW, Zochbauer S, et al: Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome. Clin Cancer Res 3:1419-1425, 1997
41. Legrand O, Simonin G, Beauchamp-Nicoud A, et al: Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood 94:1046-1056, 1999
42. Poulain S, Lepelley P, Preudhomme C, et al: Expression of the multidrug resistance-associated protein in myelodysplastic syndromes. Br J Haematol 110:591-598, 2000
43. Suarez L, Vidriales B, Garcia-Larana J, et al: Multiparametric analysis of apoptotic and multi-drug resistance phenotype in elderly patients with acute myeloid leukemia according to the blast cell maturation stage. Haematologica 86:1287-1295, 2001
44. Garrido SM, Cooper JJ, Appelbaum FR, et al: Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis. Leuk Res 25:23-32, 2001
45. Pallis M, Turzanski J, Higashi Y, et al: P-glycoprotein in acute myeloid leukaemia: Therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. Leuk Lymphoma 43:1221-1228, 2002
46. Slapak CA, Dahlheimer J, Piwnica-Worms D: Reversal of multidrug resistance with LY335979: Functional analysis of P-glycoprotein-mediated transport activity and its modulation in vivo. J Clin Pharmacol Suppl 41:29S-38S, 2001
47. Toppmeyer D, Seidman AD, Pollak M, et al: Safety and efficacy of the multidrug resistance inhibitor Incel (Biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin Cancer Res 8:670-678, 2002